2 hours ago
Description
(AWP Alliance News) - Johnson & Johnson disclosed new post-hoc analyses from its Phase 3 Vivacity-MG3 trial of IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis, with results presented at the European Academy of Neurology 2026 Congress. The additional readouts showed patients maintained symptom control across clinically relevant settings, including earlier-stage disease, lower baseline symptom burden, and periods following common infections.
Safety remained consistent with prior nipocalimab studies, with overall adverse events matching placebo and fewer serious adverse events in the treatment arm. Separately, the company outlined the PETUNIA study design, which will track real-world pregnancy, maternal, and infant outcomes following exposure to IMAAVY during pregnancy.
IMAAVY is already cleared in the U.S. and Europe for patients aged 12 and older with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis.
https://www.prnewswire.com/news-releases/johnson--johnson-presents-new-…
Disclaimer: This news brief was created using generative artificial intelligence. Johnson & Johnson published the original content used to generate this news brief via PR Newswire on June 26, 2026, and is solely responsible for the information contained therein.
